A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
A Phase 3, Randomized, Double-Blind Study of PF-05280586 Versus Rituximab for the First of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma
Category & Conditions: Cancer
Medicine: RUXIENCE™(RITUXIMAB-PVVR)
ClinicalTrials.gov Identifier (NCT): NCT02213263
Protocol ID: B3281006
PrintDownloadOpen Plain Language Summary Result: Click here